AIM IP specialist Tekcapital to sell or float all four portfolio companies 'within 2 years'. Watch the full video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Share News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 21.25
Bid: 21.00
Ask: 21.50
Change: -0.35 (-1.62%)
Spread: 0.50 (2.38%)
Open: 21.25
High: 21.25
Low: 21.20
Yest. Close: 21.60
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

Scancell reaches Covid-19 collaboration agreement with Cobra Biologics

Fri, 2nd Oct 2020 09:18

(Sharecast News) - Immunotherapies developer Scancell Holdings has entered into a collaboration agreement with Cobra Biologics to manufacture the firm's Covid-19 vaccine.

Scancell said on Friday that the pair's agreement covered Good Manufacturing Practice production of plasmid DNA needed to generate its vaccine against SARS-CoV-2 for use in a Phase 1 clinical trial in 2021.

The AIM-listed group highlighted that the project was funded by an Innovate UK grant awarded to its consortium with the University of Nottingham and Trent University.

Scancell said its vaccine had the potential to provide long-lasting immunity against Covid-19 by generating protection not only against the SARS-CoV-2 strain but also potentially against new strains of the coronavirus.

Chief executive Dr Cliff Holloway said: "Our collaboration with Cobra is critical to us moving forward with our novel SARS-CoV-2 vaccine into the planned Phase 1 clinical trial, COVIDITY.

"Cobra has the expertise needed to produce clinical-grade plasmid at scale and we look forward to working with them to advance our vaccine and demonstrate its potential effectiveness and protection against Covid-19."

As of 0915 BST, Scancell shares were up 7.46% at 18.0p.

More News

IN BRIEF: Scancell Non-Exec Director Martin Diggle buys 400,000 shares

IN BRIEF: Scancell Non-Exec Director Martin Diggle buys 400,000 shares

30 Apr 21 14:30

IN BRIEF: Associate Of Scancell Director Sells GBP109,000 In Shares

IN BRIEF: Associate Of Scancell Director Sells GBP109,000 In Shares

19 Feb 21 20:13

IN BRIEF: Scancell Non-Exec Director Diggle Sells 1.3 Million Shares

IN BRIEF: Scancell Non-Exec Director Diggle Sells 1.3 Million Shares

19 Feb 21 12:40

IN BRIEF: Scancell Non-Exec Director Diggle Sells GBP95,000 In Shares

IN BRIEF: Scancell Non-Exec Director Diggle Sells GBP95,000 In Shares

17 Feb 21 16:22

Scancell ends clinical development partnership with Cancer Research UK

(Sharecast News) - Novel immunotherapy developer Scancell updated the market on its SCIB2 clinical development partnership with Cancer Research UK on Wednesday, reporting that due to the impact of the Covid-19 pandemic and Cancer Research UK's re-evaluation of its collaboration model, the parties had agreed to end their clinical development partnership.

3 Feb 21 14:53

CORRECT: AIM WINNERS & LOSERS: Brave Bison Charges Ahead

CORRECT: AIM WINNERS & LOSERS: Brave Bison Charges Ahead

3 Feb 21 11:20

AIM WINNERS & LOSERS: Brave Bison Charges Ahead On Contract Win

AIM WINNERS & LOSERS: Brave Bison Charges Ahead On Contract Win

3 Feb 21 11:11

Scancell Assessing SCIB2 Options As Cancer Research UK Pact Ends

Scancell Assessing SCIB2 Options As Cancer Research UK Pact Ends

3 Feb 21 09:48

IN BRIEF: Scancell Posts Interim Pretax Loss; To Develop Virus Vaccine

IN BRIEF: Scancell Posts Interim Pretax Loss; To Develop Virus Vaccine

29 Jan 21 15:05

Oxford Technology VCTs In Mixed Quarter Amid Scancell Rise, Ixaris Hit

Oxford Technology VCTs In Mixed Quarter Amid Scancell Rise, Ixaris Hit

21 Dec 20 19:39

UK WINNERS & LOSERS SUMMARY: US Generic Advair Ok Lifts Hikma, Vectura

UK WINNERS & LOSERS SUMMARY: US Generic Advair Ok Lifts Hikma, Vectura

18 Dec 20 10:45

Scancell Shares Rise As It Chooses Vaccine Candidate For Development

Scancell Shares Rise As It Chooses Vaccine Candidate For Development

18 Dec 20 10:26

Scancell selects Covid-19 vaccine candidate for development and trials

(Sharecast News) - Immunotherapy developer Scancell has selected its Covid-19 vaccine candidate 'SN14' for further development and clinical trials, it announced on Friday.

18 Dec 20 10:17

DIRECTOR DEALINGS: Scancell Non-Executive Diggle Buys 750,000 Shares

DIRECTOR DEALINGS: Scancell Non-Executive Diggle Buys 750,000 Shares

16 Dec 20 09:21

UK DIRECTOR DEALINGS SUMMARY: Tracsis CFO Sells GBP480,000 In Shares

UK DIRECTOR DEALINGS SUMMARY: Tracsis CFO Sells GBP480,000 In Shares

14 Dec 20 16:59

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.